Technical Momentum and Indicator Overview
The stock closed at ₹2,017.95 on 7 Apr 2026, up from the previous close of ₹1,997.45, marking a daily increase of 1.03%. However, this short-term uptick contrasts with the broader technical landscape. The weekly Moving Average Convergence Divergence (MACD) remains bearish, signalling continued downward momentum, while the monthly MACD has softened to mildly bearish, indicating a potential easing of selling pressure but no definitive reversal yet.
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This suggests that the stock is neither overbought nor oversold, leaving room for either a recovery or further decline depending on upcoming market catalysts.
Bollinger Bands on weekly and monthly timeframes also reflect a mildly bearish stance, with the price trading near the lower band, indicating increased volatility and a potential for a rebound if buying interest strengthens. Conversely, daily moving averages remain bearish, reinforcing the short-term downtrend.
Price Range and Volatility
On the day, Mankind Pharma’s price fluctuated between a low of ₹1,966.95 and a high of ₹2,024.50, demonstrating intraday volatility within a relatively narrow band. The stock’s 52-week high stands at ₹2,726.75, while the 52-week low is ₹1,966.95, placing the current price closer to the lower end of its annual range. This proximity to the yearly low may attract value-oriented investors, but the prevailing technical signals suggest caution.
Trend Analysis and Market Context
The overall technical trend has shifted from bearish to mildly bearish, reflecting a tentative improvement but still signalling caution. The Know Sure Thing (KST) indicator on the weekly chart aligns with this mildly bearish outlook, while the monthly KST remains unclassified, indicating indecision over longer horizons.
Dow Theory analysis on both weekly and monthly charts shows no clear trend, underscoring the stock’s current consolidation phase. Similarly, On-Balance Volume (OBV) indicators do not reveal any significant directional bias, suggesting that volume trends are not confirming price movements decisively.
Comparative Performance Against Sensex
Examining returns relative to the benchmark Sensex reveals underperformance across multiple timeframes. Over the past week, Mankind Pharma gained 0.6%, lagging behind the Sensex’s 3.0% rise. The one-month return shows a decline of 7.71% versus the Sensex’s 6.10% drop, indicating the stock’s sharper correction. Year-to-date, the stock has fallen 8.12%, while the Sensex has declined 13.04%, suggesting a slightly better relative performance in 2026 so far.
Over the past year, Mankind Pharma’s return was -17.28%, significantly underperforming the Sensex’s modest -1.67%. Longer-term data is unavailable for the stock, but the Sensex’s 3-year and 5-year returns of 23.86% and 50.62% respectively highlight the broader market’s resilience compared to the stock’s recent struggles.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
Mojo Score and Grade Implications
Mankind Pharma’s current Mojo Score stands at 44.0, reflecting a cautious stance from MarketsMOJO’s proprietary rating system. The downgrade from a Hold to a Sell grade on 19 Nov 2025 signals a deterioration in the stock’s technical and fundamental outlook. This mid-cap pharmaceutical company faces headwinds from subdued price momentum and mixed technical signals, which have weighed on investor sentiment.
Investors should note that the downgrade reflects a combination of technical weakness and relative underperformance within the Pharmaceuticals & Biotechnology sector. The stock’s inability to sustain gains above key moving averages and the persistent bearish MACD readings suggest that further downside risk remains unless there is a meaningful shift in market dynamics or company fundamentals.
Technical Indicators in Detail
The weekly MACD remains below its signal line, confirming bearish momentum, though the monthly MACD’s mildly bearish status hints at a possible stabilisation in the medium term. The absence of RSI signals on both weekly and monthly charts indicates a neutral momentum environment, neither oversold nor overbought, which often precedes a directional breakout or breakdown.
Bollinger Bands’ mildly bearish readings on weekly and monthly charts suggest the stock is trading near the lower volatility band, which can sometimes precede a reversal if buying interest intensifies. However, the daily moving averages continue to slope downward, reinforcing the short-term bearish trend.
The KST indicator’s mildly bearish weekly reading aligns with the broader technical narrative of tentative weakness, while the lack of clear Dow Theory or OBV trends points to a consolidation phase without strong volume confirmation.
Holding Mankind Pharma Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaways and Outlook
For investors, the current technical landscape of Mankind Pharma Ltd suggests a cautious approach. The stock’s proximity to its 52-week low and the mildly bearish technical indicators imply that downside risks persist. The lack of strong bullish signals from momentum indicators such as MACD and RSI means that any recovery may be tentative and require confirmation through sustained volume and price action above key moving averages.
Relative underperformance against the Sensex over the past year further emphasises the need for careful stock selection within the Pharmaceuticals & Biotechnology sector. While the sector itself may offer growth opportunities, Mankind Pharma’s current technical profile and Mojo Grade downgrade indicate that investors might consider alternative names with stronger momentum and more favourable technical setups.
Monitoring upcoming quarterly results, sector developments, and broader market trends will be crucial for reassessing the stock’s outlook. Until then, the mildly bearish technical stance and the recent downgrade suggest that Mankind Pharma remains a stock to watch with prudence rather than aggressive accumulation.
Summary of Technical Signals
In summary, Mankind Pharma Ltd’s technical indicators present a mixed but predominantly cautious picture:
- MACD: Weekly bearish, monthly mildly bearish
- RSI: Neutral on weekly and monthly charts
- Bollinger Bands: Mildly bearish on weekly and monthly
- Moving Averages: Daily bearish trend
- KST: Weekly mildly bearish, monthly unclassified
- Dow Theory and OBV: No clear trend
These signals collectively point to a stock in consolidation with a slight bearish bias, requiring confirmation before any meaningful trend reversal can be expected.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
